This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Aclerastide

Derma Sciences, Inc.

Drug Names(s): DSC127, Angiotensin, DSC-127, NorLeu3-A(1-7), USB-001, USB001

Description: DSC127 is an analog of a naturally occurring peptide, Angiotensin II. It consists of a fragment of angiotensin II with modifications (NorLeu3-Angiotensin(1-7)). Angiotensin(1-7) apparently does not raise blood pressure like angiotensin, but rather has a vasodilatory effect (it also may inhibit cyclooxygenase 2 (COX-2)).

DSC127 has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization. Additionally, histological examination has shown that DSC127 accelerated collagen deposition six-fold.

The action of NorLeu3-A(1-7) in healing in a couple of rodent models was blocked by the A(1-7) receptor antagonist d-Ala7-angiotensin(1-7), so the specific receptor appears to be involved.Up-regulation of mesenchymal stem cells (MSCs) at the site of injury may also be involved. While there is some evidence of similar effects of angiotensin (1-7) and angiotensin II on wound healing, there is also evidence for opposing effects on fibrovascular tissue growth, which was ehanced by angiotensin II but reduced by angiotensin (1-7).


Aclerastide News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug